INS and type 2 diabetes mellitus: The positive control drug, gliclazide sustained-release tablet, is the second-generation sulfonylurea oral hypoglycemic agent, and it is one of the first-choice drugs in clinical treatment of T2DM with nonobesity, normal or low fasting insulin levels.